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MENGANALISIS Andrographis paniculata, Eurycoma /ongifolia DAN Phyl/agathis 
rotundifolia UNTUK AKTIVITI ANTI-MALARIA TERHADAP PARASIT 
MALARIA RINTANG CHLOROQUINE DAN MEFLOQUINE 
ABSTRAK 
Kemunculan parasit malaria yang rintang terhadap ubat merupakan salah satu daripada 
masalah kesihatan yang utama di dunia dan pencarian rawatan barn adalah suatu 
keutamaan. Tumbuh-tumbuhan masih menjadi satu sumber semulajadi yang penting 
untuk penjagaan kesihatan bagi kebanyakan orang. Walau bagaimana pun, bukti 
saintifik diperlukan untuk menyokong dabvaan sedemikian. Matlamat kajian ini ialah 
pertamanya untuk menentukan aktiviti antimalaria Andrographis paniculata (A. 
paniculata) terhadap strain Plasmodium falciparum (P. falciparum) yang rintang kepada 
chloroquine (CQ) dan mefloquine (MQ) dan kesannya apabila digabungkan dengan CQ 
atau MQ. Tujuan kajian yang kedua adalah untuk mengkaji kesan A. paniculata dan E. 
/ongifolia apabila digabungkan dengan CQ terhadap Plasmodium berghei (P. berghei) 
yang rintang kepada CQ. Manakala matlamat kajian yang terakhir adalah untuk 
menentukan kesan Phyllagathis rotundifolia (P. rotundifolia) bagi ekstrak air dan etanol 
terhadap P. berghei (rintang kepada CQ dan MQ). P. falciparum strain Dd2 telah 
dikultur dan asai secara in vitro telah dilalcukan dengan menggunakan pelbagai 
kepekatan CQ dan MQ secara individu dan gabungan dengan pelbagai kepekatan A. 
paniculata. Parasit dilabel dengan 3H-hypoxanthine dan penggabungan isotop 
ditentukan. Nilai kepekatan perencatan 50% (IC50) bagi CQ, MQ dan pelbagai gabungan 
CQ-A paniculata dan MQ-A. paniculata telah ditentukan dengan analisis probit dan 
XIX 
isobologram. Keputusan menunjukkan terdapat kesan sinergistik gabungan A. 
paniculata dengan CQ dan MQ. Dalam kajian in vivo, kumpulan tikus Swiss Albino 
diinokulat secara intraperitoneal dengan sel darah merah yang telah dijangkiti dengan 
Plasmodium berghei yang rintang kepada CQ (NK65) atau MQ {Nll 00) dan telah 
dirawat sama ada dengan CQ, A. paniculata, E. longifolia, pelbagai gabungan CQ-A. 
paniculata atau MQ-E. longifolia atau dengan ekstrak air atau etanol P. rotundifolia. CQ 
pada dos 10 mglkglhari telah dipilih untuk kajian gabungan. A. paniculata dan E. 
longifolia menunjukkan aktiviti antimalaria yang positif terhadap P. berghei (NK65) 
yang rintang kepada CQ. A. paniculata sahaja mempunyai kesan yang lebih efektif 
berbanding dengan E. longifolia. Gabungan E. longifolia dengan CQ telah 
memanjangkan kadar kemandirian tikus. Kesan yang sama tidak kelihatan apabila A. 
paniculata digabung dengan CQ. Rawatan dengan P. rotundifolia pada dos yang tinggi 
telah memanjangkan kadar kemandirian tikus yang telah dijangkiti dan ekstrak etanol P. 
rotundifolia terbukti lebih poten dibanding dengan ekstrak air NK65 dan Nll 00. 
Kesimpulan, gabungan CQ dan MQ dengan A. Paniculata menunjukkan kesan 
sinergistik in vitro. A. paniculata dan E. longifolia mempunyai kecenqerungan untuk 
membaikpulih kerintangan P. berghei terhadap CQ. Gabungan ekstrak E. longifolia 
dengan CQ memberikan kesan antimalaria yang lebih baik berbanding dengan gabungan 
A. paniculata dengan CQ. Ekstrak air dan etanol P. rotundifolia menunjukkan aktiviti 
antimalaria terhadap P. berghei yang rintang kepada CQ atau MQ. Kajian interaksi 
antara CQ dan MQ dengan bahan aktif utama herba-herba adalah amat dicadangkan. 
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EVALUATION OF Andrographis paniculata, Eurycoma longifolia AND 
PhyUagathis rotundifolia FOR ANTIMALARIAL ACTIVITY AGAINST 
CHLOROQUINE AND MEFLOQUINE RESIST ANT MALARIAL PARASITES 
ABSTRACT 
The emergence of drug resistant malaria parasite is one of the major health problems in 
the world and the search for new treatment is increasingly becoming a priority. Plants 
remained an important natural source of health remedy for mankind. However, scientific 
evidence is crucial to support claims of health benefits. The objectives of this study 
firstly to determine the antimalarial activity of Andrographis paniculata (A. paniculata) 
against chloroquine (CQ) and mefloquine (MQ) resistant Plasmodium falciparum (P. 
falciparum) strain and their efficacy in combination with CQ or MQ. Secondly to study 
the efficacy of A. paniculata and E. longifolia in combination with CQ against CQ 
resistant Plasmodium berghei (P. berghez). Lastly to determine the effect of water and 
ethanol extract of Phyllagathis rotundifolia (P. rotundifolia) on P. berghei (CQ and MQ 
resistant strain). P. falciparum Dd2 strain was cultured and in vitro assays were done 
with various concentrations of CQ and MQ individually and in combination with various 
concentrations of A. paniculata. Parasites were labeled with 3H-hypoxanthine and 
incorpomtion of radio labeled isotope was determined. The 50% inhibitory concentration 
(IC5o) values of CQ, MQ, A. paniculata and various combination of CQ-A. paniculata 
and MQ-A. paniculata were determined by probit analysis and isobologram. Results 
indicated that there were synergistic effect towards CQ and MQ. In the in vivo studies, 
groups of Swiss Albino mice were inoculated intraperitoneally with CQ (NK65) or MQ 
XXI 
resistants (NllOO) of Plasmodium berghei infected erythrocytes and were treated either 
with CQ, A. paniculata or E. longifolia, various combinations of CQ/A. paniculata and 
CQIE. /ongifo/ia or With P. rotundifolia water or ethanol extracts. A CQ dose of 10 
mg/kg/day was selected for the combination study. A. paniculata and E. Iongifo/ia 
showed positive antimalarial activities against CQ resistant P. berghei (NK65). A. 
panicu/ata alone appeared to be more effective compared to E. longifo/ia. Combination 
of E. longifolia with CQ prolonged the survival rate of the mice. Similar effect was not 
seen when A. paniculata was combined with CQ. Treatment with high dose of P. 
rotundifolia prolonged the survival rate of infected mice and the ethanol extract of P. 
rotundifolia proved to be more potent compared to the water extract against NK65 and 
NllOO. In conclusions, a combination of CQ and MQ with A. paniculata revealed 
synergistic effect in vitro. Both A. paniculata and E. /ongifo/ia have the tendency to 
reduce the resistance of P. berghei to CQ. Combination of E. longifolia extract with CQ 
was superior compared to the combination of A. paniculata with CQ. Both ethanol and 
water based extract of P. rotundifolia showed antimalarial activity against CQ/MQ 
resistant P. berghei. Interaction studies between CQ and MQ with the active compound 
of the herbs are highly recommended. 
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CHAPTER I 
Introduction 
Malaria is one of the most common infectious diseases and a major public health 
problem. It is a vector-borne disease found widespread in tropical and subtropical 
regions, including parts of the Americas, Asia and Africa. Each year approximately 300-
500 million people are infected with the parasite and of these up to 3 million succumb, 
most of them young children in Sub-Saharan Africa (White, 1992). Almost all deaths are 
caused by Plasmodium falciparum (P. falciparum), one of the four species of malaria 
parasites in human. The others are Plasmodium vivax (P. vivax), Plasmodium ovale (P. 
ova/e) and Plasmodium malariae (P. malariae). 
According to WHO, it has been estimated that there were 247 million malaria cases 
worldwide in 2006 and the m~ority of cases (86%) were in the African followed by 
South-East Asia (9%) and Eastern Mediterranean regions (3%). 
Even though intensive efforts have been taken to control malaria, the disease continues 
to be one of the greatest health problems. Quinine is an antimalarial drug that has been 
used for more than three centuries and until 1930's, it was the only effective agent for 
the treatment of malaria It is one of four alkaloids found in the bark of cinchona tree 
and the only drug that has remained useful for treating the disease. 
Early in the 20th century, wartime pressure propelled research towards its synthetic 
production. It was also during this same period that the discovery and evaluation of 
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many series of organic compounds, which include pamaquine and quinacrine after 
World War 1 and at last produced chloroquine (CQ) in 1934. The popularity of CQ has 
been due to its efficacy and the low risk of side effects when used in prescribed doses. It 
is also the cheapest, time tested and safe anti malarial agent. The tremendous use of CQ 
for treatment of P. falciparum malaria led to the wide spread problem of CQ resistance 
strain of P. falciparum in the affected regions (Peters, 1982). 
Drug resistance is defined as the ability of a parasite strain to survive the administration 
and absorption of a drug given in doses equal to or higher than those usually 
recommended, but within the limits of tolerance of the subjects (Clyde et a!., 1973). 
Malaria resistance to CQ was first reported in the late 1950s in South America and 
Southeast Asia and has spread to nearly all regions where malaria is endemic (Marsh, 
1998). In Malaysia, CQ resistance case was first reported in 1965 (Montgomery and 
Eyles, 1963), and subsequently, several CQ resistant cases have been reported in Sabah 
(Clyde et al., 1973). Today CQ resistance covers almost the entire wqrld, except for 
some countries in Central America and some Caribbean islands (Wongsrichanalai et al., 
2002). 
Mefloquine (MQ) was introduced in 1970s to treat CQ resistant malaria, which was 
better tolerated and as effective as CQ. It has proven to be effective especially against 
CQ resistant strain (Palmer et a!., 1993). However, resistance to MQ has been rising 
since this drug was introduced. In Thailand, within 5 years MQ resistance was 
developed because of intensively used (White, 1992). 
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In general, resistance occurs through spontaneous mutations that confer reduced 
sensitivity to a given drug. For some drugs, only a single point mutation is required to 
confer resistance, while for other drugs, multiple mutations are required. Provided the 
mutations are not deleterious to the survival or reproduction of the parasite, drugs 
remove susceptible parasites while resistant parasites survive (Thaithong, 1983). Other 
important factors implicated in the development of resistance are long half-life, poor 
compliance, host immunity and widespread use these drugs. 
Successful strategies to prevent drug resistance generally focus on reducing overall drug 
pressure through more selective use of drugs, improving the way drugs are used through 
improving prescribing, follow-up practices, and patient compliance. Next approach by 
using drugs or drug combinations which are less likely to foster resistance and lastly 
enclose properties that do not facilitate development or spread of resistant parasites 
(WHO, 2001 ). 
Current antimalarial drugs are often ineffective because of the increasing resistance of P. 
falciparum and in the search for new antimalarial agents, natural product might be 
considered as a source of new potentially active compounds. 
Actually, around 80% of the world's population still depend on traditional medicine as a 
source for disease treatment (Zirihi et al., 2005). In Brazil, people in rural areas rely 
mostly on traditional medicine for the treatment of many infectious diseases. Traditional 
healthcare in South African are also commonly used medicinal plants to treat ailment, 
including malaria and its associated symptoms. For the countries where malaria. is 
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endemic, the use of traditional and herbal remedies are an alternative choice of treatment 
(Gessler et a/., 1995; Rasoanaivo et a/., 1992). Clarkson et a/., (2004) reported that 
historically, the majority of antimalarial drugs are derived from medicinal plants, 
including the quinoline-based antimalarials as well as artemisinin and its derivatives. 
Malaysia is known as a country that treasures its natural forests and is rich in natural 
resources basic to traditional medicine. There are over 6000 species of tropical plants in 
the country and in Peninsula Malaysia there are 550 genera containing 1300 species 
(Zakaria and Mohd, 1994). Malaysians also practice traditional and herbal remedies as 
an alternative choice in the treatment of disease by using plant products such as leaves, 
roots and stems as ingredients in traditional medicine preparation. 
Therefore, it is important that medicinal plants, which have reputation for antimalarials 
properties are investigated, in order to determine their potential and to establish their 
efficacy as a sources of new antimalarial drugs. 
Malaysian medicinal plants used in this study were E. /ongifolia (tongkat ali), A. 
paniculata (hempedu bumi) and P. rotundifo/ia (tapak sulaiman). The first two herbs E. 
/ongifolia and A. paniculata have been reported to have antimalarial activities. They are 
popular herbs used traditionally by many Malaysians as anti-pyretic and anti-malarial 
(Kuo et a/., 2004; Dua et a/., 2004). In addition, E. longifo/ia was used traditionally as 
an aphrodisiac and for improving general health, hypertension and glandular swelling 
(Ang et a/., 2000). A. paniculata was also used traditionally as analgesic, expectorant, 
digestive, stomachic, antipyretic and also used to treat worm infection. 
4 
Studies have shown that E. longifolia has antimalarial activity in vitro, an effect which is 
due to multiple constituents of the plant (Kuo et a/., 2004). In an animal study, E. 
longifolia had the ability to improve survival in P. berghei infected animals, but the 
effective dose was near toxic. E. longifolia also has an anticancer effect against multiple 
cancer cell lines and is effective against multiple parasites in vitro (Ang and Cheang, 
1999; Jiwajinda eta/., 2002). 
For A. paniculata, a study that has been done by Misra et a/ (1992) found that the crude 
methanol extract of A. paniculata could reduce the parasitemia condition that caused by 
P. berghei NK65. Neoandrographolide compound that contained in the plant has the 
ability to prevent the parasitic infection. 
Purl et a/., (1993) has shown that in mice, an extract of A. paniculata is an effective 
stimulator of the immune system for responses, antigen specific response and 
nonspecific immune response. This extract activated both responses by making it 
effective against a variety of infectious and oncogenic (cancer-causing) agents. 
E. longifolia and A. paniculata extracts have shown inhibitory effects on the growth of 
malaria parasites in earlier studies. However, no attempt has been made to reverse 
CQIMQ P. falciparum resistance by combining CQ or MQ with herbal medicine such as 
with E. longifolia or A paniculata. Hence this study aims to evaluate potential of these 
herbs as resistance reversal agents in combination with CQ or MQ. Regarding P. 
rotundifolia, there have been no studies done for its antimalarial activity. Therefore, this 
study is proposed to discover its antimalarial activity. 
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Study objectives: 
1. To study the effect of Andrographis paniculata water based extract on CQ/MQ 
resistant Plasmodium falciparum in vitro. 
2. To study the combination effect of Andrographis paniculata with CQ and MQ 
against CQ/MQ resistant Plasmodium falciparum in vitro. 
3. To study the combination effect of Andrographis paniculata with CQ against 
CQ resistant Plasmodium berghei in vivo. 
4. To study the combination effect of Eurycoma longifolia with CQ against CQ 
resistant Plasmodium berghei in vivo. 
6. To study the effect of Phyllagathis rotundifolia (water and ethanol extracts) on CQ 
resistant P. berghei in vivo. 
7. To study the effect of Phyllagathis rotundifolia (water and ethanol extracts) on MQ 
resistant P. berghei in vivo. 
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CHAPTER2 
Literature Review 
2.1 Epidemiology of malaria 
Malaria is caused by protozoan parasites of the genus Plasmodium. There are four 
species of Plasmodium that infect human, Plasmodium falciparum (P. falciparum), 
Plasmodium vivax (P. vivax), Plasmodium malariae (P. malariae) and Plasmodium 
ovale (P. ovale). P. falciparum is responsible for nearly all malarial deaths (Karou eta/., 
2003). All four species are transmitted from infected person to another person by female 
Anopheles mosquitoes. 
P. falciparum is predominant in Africa, it can cause severe malaria because it multiplies 
rapidly in the blood and resulted in severe red blood cell loss (anemia). P. vivax is found 
mostly in the middle East, lower Korean peninsular and some parts of Africa (Hamer et 
al., 2003). This species produces less severe symptoms but can remain in the liver and 
causes relapse for up to three years. P. malariae occurs in tropical Africa, Sri Lanka, 
Myanmar and parts of India It can cause typical malaria symptoms but on rare 
occasions it remains in the bloodstream for years without producing any symptoms. P. 
ovale is mainly found in Africa and considered as a rare species in South-east Asia 
(Kreier and Baker, 1987). 
Malaria continues to be a public health problem of high priority in the majority of 
malarial endemic countries (Figure 2.1 ). Malaria occurs mostly in tropical and sub-
tropical regions. 
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The occurrence of malaria depends on the vector (Anopheles mosquito), the plasmodium 
(parasites) and the host (human being). Anopheles mosquito is in contact with human. 
The parasites complete half of their life cycle in the invertebrate host and half of their 
life cycle in the human. Factors that influence the above three things will influence the 
occurrence of malaria 
Climate can influence the occurrence of malaria (Sutherst, 1998). It is a key determinant 
for geographic distribution and the seasonality of malaria Rainfall creates collections of 
water (breeding site) where Anopheles eggs are deposited, and larvae and pupae develop 
into adulthood. Once adult mosquitoes have emerged, the ambient temperature, humidity 
and rains will determine their chances of survival. To transmit malaria parasite 
effectively, female Anopheles mosquitoes must survive long enough after they have 
been infected to allow the parasites to complete their growth cycle. The complete cycle 
takes 9-21 days at 25°C or 77°F. Warmer ambient temperatures shorten the duration of 
the growth cycle, thus increasing the chances of transmission. By contrast, below the 
minimum ambient temperature {15°C or 59°F for P. vivax, 20°C or 68°F for P. 
falciparum ), the growth cycle could not be completed and malaria parasites could not be 
transmitted. This explains why the malaria transmission is greater in warmer areas, 
especially for P. falciparum. 
The spread of malaria depend on number of mosquitoes and their behaviour. 
Development of mosquitoes population is strongly influenced by the climate. 
Temperature, rainfall, humidity all affects mosquito populations, as well as other 
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climatic factors, such as wind and sunlight. Increased rainfall and higher temperatures 
may provide more breeding pools for mosquitoes and can speed up the development of 
mosquito larvae into adults (Hunter, 2003 ). The climate also determines human 
behaviours. Hot weather may encourage people to sleep outdoors and discourage them 
from using bed nets. So they have no protection against mosquito bites. Global warming 
and climate change may increase the geographic range of malaria and may be 
responsible for malaria epidemics (Sutherst, 1998). 
Other factors that affect malaria transmission include environmental modification (e.g. 
deforestation, increases in irrigation, swamp drainage), population gro~ limited 
access to health care systems, and lack of or unsuccessful malaria control measures 
(Bouma et al., 1996). · 
The geographic distribution of malaria within large regions is complex, and malaria-free 
region is always found close to each other (Greenwood and Mutabingwa, 2002). 
Malaria is more common in rural than in urban areas. For example, the .urban areas in 
the Vietnam, Laos and Cambodia are essentially malaria-free, but the disease is present 
in many rural regions (Trung et al., 2004). By contrast, in Africa malaria present in both 
rural and urban areas, though the risk is lower in the larger cities (Keiser et al., 2004 ). 
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Figure 2.1 Areas ofthe world where malaria is endemic in the 21st century 
Source: WHO, 2001. 
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2.2 Anopheles mosquito 
There are many species of mosquitoes that transmit pathogens and causing disease in 
human. The Culex pipien or the "northern house" mosquito transmit virus that cause 
yellow fever in humans. Other species like Aedes albopictus mosquito also can transmit 
yellow fever and dengue fever. Only female Anopheles mosquitoes can transmit the 
Plasmodium species, which cause malaria in human. This species are found worldwide 
except in Antartica and have been reported to be the most notorious of all vectors of 
disease to human (Brogdon and McAllister, 1998). 
Anopheles gambie, Anopheles arabi ens is and Anopheles funentus are the three vectors in 
Africa, where the majority of malaria cases and deaths occur. Malaria is transmitted by 
different Anopheles species, depending on the region and the environment Anopheles 
mosquitoes are easily distinguished, as an adult rest at an angle to the surface on which 
they rest but other mosquitoes rest with their body parallel to the surface (Figure 2.2). 
Anopheles mosquito's bite at night and their breeding site are primarily in rural areas. 
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Figure 2.2 : Mosquito feeding on human arm. 
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Each Anopheles species are different in behavior traits. Some species prefer to get their 
blood meals from humans ("anthropophilic") while in others they prefer animals 
("zoophilic"). Other species prefer to bite outdoors ("exophagic"), and some prefer 
indoor biting ("endophagic"). So the anthropophilic and endophagic species will have 
more frequent contacts with humans and thus will be more effective malaria vectors. 
Besides, some species prefer to rest inside the dwellings where they have just obtained 
their blood meals ("endophilic") while others prefer to rest outdoors ("exophilic"). 
Anopheles mosquito need to be controlled in order to prevent malaria as well as other 
mosquito-borne disease. Vector control aims to decrease contacts between humans and 
vectors of human disease. Vector control for the prevention of malaria includes 
insecticide-treated bed nets, indoor residua spraying and source reduction (larval 
control). 
A form of personal protection that has been shown to reduce severe disease and 
mortality due to malaria in endemic regions was Insecticide-treated bed nets (ITNs). The 
usually used untreated bed nets also a form of protective barrier for the persons using 
them. Nevertheless, mosquitoes still can feed on people through the nets because the 
nets have small holes. The application of ITNs greatly enhances the protective efficacy 
of bed nets. The insecticides used for treatment kill mosquitoes and other insects (CDC, 
2008). 
At present, only pyrethroid insecticides are approved for use on ITNs. This insecticide 
has very low mammalian toxicity but is highly toxic to insects and has very good effects, 
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even at very low dose. Pyrethroids have high residual effects, they do not rapidly 
degrade unless washed or exposed to sunlight. 
The second mode for vector control is indoor residual spraying. Endophilic vectors are 
susceptible to control through indoor residual spraying (IRS). IRS does not directly 
prevent people from being bitten by mosquitoes. On the contrary, it kills mosquitoes 
after they have fed, if they come to rest on the sprayed surface. As a result IRS prevents 
transmission of infection to other persons. Nevertheless, if the mosquitoes resistant to 
the insecticide used, these measures will not be effective in restraining the transmission. 
The third mode for vectors control is by source reduction, through an excellent water 
management system. The larval habitats may be destroyed by filling depressions that 
collect water, by draining swamps, or by ditching marshy areas to remove standing 
water. Besides that, container-breeding mosquitoes are particularly susceptible to source 
reduction as people can be educated to remove or cover standing water in cans, cups, 
and rain barrels around houses. Fogging or area spraying, stop epidemics or rapidly 
reducing adult mosquito populations when they have become abundant. Fogging and 
area sprays must be properly timed to coincide with the time of peak adult activity, 
because resting mosquitoes are often found in areas that are difficult for the insecticide 
to reach e.g. under leaves, in small crevices (CDC, 2008). 
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2.3 Life cycles of Plasmodium 
Life cycle of P. falciparum develops via two different phases, which are asexual phase 
in man and sexual phase in mosquito (Figure 2.3). All four species exhibit a similar life 
cycle with only minor variations. 
During blood meal, a malaria-infected female Anopheles mosquito inoculates 
sporozoites into the human host. The sporozoites enter the liver and invade human liver 
cells to form hepatic throphozoites. Within two days, internal divisions begin and the 
throphozoite become schizont. Between 5.5 to 15 days, mature schizonts rupture and 
release about 1000 merozoites. 
After this initial replication in the liver (exo-erythrocytic cycle), the parasite undergoes 
asexual multiplication in the erythrocyte (erythrocytic cycle). Merozoites released from 
the liver schizont invade the erythrocyte. After 20 minutes invading, the merozoites 
develop into trophozoites. The early trophozoites are referred as 'ring form' because of 
its morphology. Trophozoites enlarge in .size and form irregular shape to become 
amoeboid form. Amoeboid form is also known as late trophozoite, formed when its 
reaches a certain stage of development and till the time its nucleus start dividing. Early 
schizonts form when the nucleus divides into many small nuclei while the cytoplasm 
remaining intact and undivided. Mature schizonts appear when the daughter nucleus is 
surrounded by cytoplasm. Small rounded merozoites are seen in the matures schizonts, a 
fully grown form. When the process of schizogony is completed the red cell burst and 8-
16 merozoites are released into blood stream. Bursting of the merozoites release all 
debris and thus will cause febrile episode in the host. A new cycle of erythrocytic 
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schizogony starts when merozoites invade fresh erythrocytes again, leading to increased 
of parasitaemia. 
The parasite can differentiate into sexual erythrocytes forms (gametocytes ). The 
gametocytes are large parasites, which fill up the erythrocyte and only contain one 
nucleus. The microgametocytes (male) and macrogametocytes (female) are ingested by 
an anopheles mosquito during blood meal. The parasite's multiplication in the mosquito 
is known as the sporogonic cycle. While in the mosquito's stomach, the micro gametes 
penetrate the macrogametes generating zygotes. The zygote develops into motile 
ookinete, which penetrates the gut epithelial cells and develops to an oocyst. The oocysts 
grow, rupture and release sporozoites. The sporozoites migrate to the mosquito's 
salivary glands. Inoculation of the sporozoites into a new human host perpetuates the 
malaria life cycle (Chatterjee, 1979). In all 4 species, asexual multiplication takes place 
within the liver cells, but with P. vivax and P. ovale a varying proportion of the infecting 
sporozoites enters a resting.-stage before undergoing asexual multiplication, while others 
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undergo this multiplicatior;_, .,-itltout delay. The resting stage of parasite is known as 
hypnozoite. After a period of weeks or months, reactivation of the hypnozoite initiates 
asexual division. 
While hypnozoites have not been observed in human infections, their presence in P. 
vivax and P. ovale is inferred from experimental observations (Krotoski, 1985). Other 
characteristics ofthe four species ofhuman Plasmodia are summarized in table 2.1. 
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Table 2.1: Some differences of four species ofhuman Plasmodia. 
P. vivax P. ovate P. ma/ariae P. fa/ciparum 
Pre-erythrocitic 8 9 13 5-6 
cycle (days) 
Pre-patent 11-13 10-14 15-16 9-10 
period (days) 
Incubation 13 (12-17) 17 (16-18) 28 (18-40) 12 (9-14) 
period (days) 
Number of Over 10,000 15,000 2,000 40,000 
merozoites/ 
tissue schizont 
Hypnozoites Present Present Absent Absent 
Erythrocitic 48 50 72 48 
cycle (hours) 
Average 20,000 9,000 6,000 20-500,000 
parasitaemia I 
Ill 
Maximum 50,000 30,000 20,000 2,000,000 
parasitaemia I 
,.u 
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Figure 2.3: SchemakC"'diagram ofthe life cycle of malaria (adapted from 
http://www .malariatest.com/cycle.html) 
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2.4 Signs and symptoms of malaria 
Symptoms caused by infection with plasmodium closely associated with the parasite's 
life cycle. The clinical symptoms of malaria are primarily due to schizont rupture and 
red blood cells destruction. Usually presentation of malaria resembles common viral 
infections which may delay the diagnosis (Murphy and Oldfield, 1996).The majority of 
patients experience fever (>92% of cases), chills (79'1/o), headaches (70%) and 
diaphoresis (64%). Other symptoms of malaria include arthralgia Goint pain), vomiting, 
abdominal pain, dizziness, dry cough and malaise (Kreier and Baker, 1987). 
The classical symptom of malaria is cyclical occurrence of sudden coldness followed by 
rigor and then fever and sweating lasting for four to six hours, occurring every two days 
in P. vivax and P. ovate infections, while every three hours for P. malariae. Life P. 
falciparum infection, there is usually recurrent fever every 36-48 hours or a less 
pronounced and almost continuous fever. In P. jalciparum it may be associated with 
increase in intracranial pressttte. Children with P. falcparum malaria frequently exhibit 
,_ 
abnormal posturing, a sign ~<jicating severe brain damage (Medana et a~~· 2007). The 
different presentation for malaria caused by P: falciparum isl poorly understood. 
Almost all severe forms and deaths from malaria are caused by P. falciparum and 
usually arises 6-14 days after infection (Trampuz eta!., 2003). It is rare for P. ovale and 
P. vivax to produce serious complications or death (Svenson et a!., 1995). The major 
complications of severe malaria include cerebral malaria, pulmonary oedema, acute 
renal failure and severe anemia. Acidosis and hypoglycemia are the most common 
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metabolic complications. Any of these complications can develop rapidly and progress 
to death within hours or days (Wongsrichanalai et al., 2000). 
In cerebral malaria, red blood cell infected with the parasite can adhere to the lining of 
small blood vessels, when this occur in brain blood vessels, it can cause oxygen 
deprivation to the brain and tissue damage. For severe anemia, constant infection of the 
red blood cells by malaria parasites can lead to depletion of red blood cell, particularly 
in children, who have not built resistance. Meanwhile, renal failure may occur in 
blackwater fever, where hemoglobin from lysed red blood cells leak into the urine. 
In earlier studies, risk factors for severe malaria and death include nonimmune status, 
age greater than 65 years, no antimalarial prophylaxis status, co-existing medical 
conditions, delay in treatment and severity of the illness at admission. In tropical 
countries with a high transmission of malaria (hyperendemic areas), severe malaria is 
predominantly a disease ofJoung children (1 ~onth to 5 years of age) and the fatality 
rate for severe malaria m~ ,.,exteed 20% even when managed in intensive care units 
(Kain et a/., 1998). 
In 1990, World Health Organization (WHO) established the criteria for severe malaria 
in order to assist future clinical and epidemiological studies. Ten years later WHO 
revised the criteria to include other clifljcal manifestations and laboratory values 
(Wongsrichanalai et a/., 2000). Table 2.1 is showing the criteria for severe malaria 
provided by WHO in 1990 and the additional criteria proposed in 2000. 
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Chronic malaria is seen in both P. vivax and P. ovale, but not in P. falciparum. The 
disease can relapse for months or years after exposure, this is due to the presence of 
latent parasites in the liver and the longest incubation period reported for a P. vivax 
infection is 30 years (Trampuz eta/., 2003). 
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Table 2.2 Severe malaria and poor prognosis indicators. 
Manifestation Features 
Initial WHO criteria from1990 
Cerebral malaria Unrousable coma not attributable to any other cause, 
with a Glasgow Coma Scale S9. Coma should persist for 
at least 30 min after a generalized convulsion. 
Severe anemia Hematocrit <15% or hemoglobin <50 gil in the presence 
of parasite count > 10 000/J.Ll. 
Renal failure Urine output <400 ml/24 hours in adult (<12 ml/kg/24 
hours in children) and a serum creatinine >265 JlffiOlll 
(>3.0 mgldl) despite adequate volume repletion. 
Pulmonary edema and acute The acute lung injury score is calculated on the basis 
respiratory distress syndrome of radiographic densities, severity of hypoxemia and 
positive end-respiratory pressure. 
Hypoglycemia Whole blood glucose concentration <2.2 mmol/1 (<40 
mgldl). 
Circulatory collapse Systolic blood pressure <70 mmHg in patients >5 years 
of age with cold clammy skin or a core~skin temperature 
difference >I 0°C. 
Abnormal bleeding Spontaneous bleeding from gums, nose, gastrointestinal 
tract or laboratory evidence of disseminated intravascular 
coagulation. 
Repeated generalized convulsions > 3 convulsions observed within 24 hours. 
Acidemia 
.. ¥ .. < Arterial pH <7 .25 or acidosis 
Macroscopic hemoglobinuria Hemolysis not secondary to glucose-6-phosphate 
#- dehydrogenase deficiency. 
.-< 
Added WHQ criteria from 2000 
Impaired consciousness Rousable mental condition 
Hyperparasitemia >5% parasitized erythrocytes or >250 000 parasites/J.Ll 
Hyperpyrexia Core body temperature >40°C 
Hyperbilirubinemia Total bilirubin >43 J:liilOl/l 
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2.5 Treatment and prevention of malaria 
2.5.1 Prevention of malaria 
Malaria prevention aims to protect a person against mosquito bites. There are two ways 
for prevention of malaria. First avoiding being bitten by a mosquito which carrying the 
malaria parasite. WHO has been working to eradicate malaria for more than thirty years. 
Its approach is to kill as many of the mosquitoes that cause malaria as possible. Its used 
pesticide to kill mosquitoes but unluckily mosquitoes have slowly become resistant to 
many pesticides. Because of that, its become more difficult to kill mosquitoes with the 
available pesticides (CDC, 2008). 
The second way for avoiding malaria is by taking drugs that protect against the disease. 
These drugs will kill the parasites as they enter the bloodstream. But this approach also 
have problem as anti-malarial drugs are expensive. Most people in Africa, Asia, and 
other areas where malaria is common cannot afford them. 
"' Beside that, researchers really hoped to find vaccine for malaria. With vaccine, we could 
be protected for a lifetime with one or a few shots. Nevertheless, researchers have not 
been successful in producing such a vaccine. In addition, other preventive measures 
could also be followed, including wearing clothes that cover the entire body, sleep inside 
mosquito nets that have been soaked with mosquit~ repellent as described before or 
staying indoors in window-screened areas between dusk and dawn (Hardman and 
Limbird, 200 I). 
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2.5.2 Treatments of malaria 
Malaria can be a severe, potentially fatal disease (especially when caused by P. 
falciparum) and treatment should be initiated as soon as possible. 
In endemic areas, WHO recommended that treatment should be started within 24 hours 
after the first symptoms. Patients with severe malaria are preferably hospitalized but 
patients with uncomplicated malaria are treated as outpatient. Areas where malaria is not 
endemic, it is recommended that all patients with malaria (uncomplicated or severe) be 
kept under clinical observation if possible. 
2.5.2.1 Antimalarial drugs 
Antimalarial drugs are designed to prevent or cure malaria. There are many antimalarial 
drugs currently available in the market and quinine is the oldest and most popular 
antimalarial. There are two types of antimalarial, prophylactic and therapy drugs. 
Prophylactic drugs are taken as prevention and require continuous administration to 
reduce the risk of infection. Meanwhile, therapy drugs are in use once the person already 
.;- " 
gets the infection (Chen and Keystone, 200.5). 
2.5.2.1.1 Chloroquine (CQ) 
CQ with molecular weight (MW) 515.87 is a white and crystalline powder. It is soluble 
in water and stable at room temperature with 200°C melting temperature. CQ is the 
prototype anti malarial drug and most ""idely used to treat all types of malarial 
infections. It is also the cheapest, time tested and safe anti malarial agent. CQ is one of a 
large series of 4-aminoquinolines discovered in the 1940's and is highly effective 
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